Astellas Pharma ALPMY

OTC: ALPMY | ISIN: US04623U1025   10/05/2024
9,720 USD (-1,82%)
(-1,82%)   10/05/2024

8 mei 2024 · Astellas Unveils New, State-of-the-Art, $90 Million West Coast Innovation Center in the South San Francisco Biotech Corridor · Persbericht

2 mei 2024 · Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology · Persbericht

24 april 2024 · Astellas' XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting · Persbericht

22 april 2024 · Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs · Persbericht

28 maart 2024 · China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for enfortumab vedotin with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer · Persbericht

26 maart 2024 · Astellas Receives Permanent J-code for IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy · Persbericht

26 maart 2024 · Astellas' VYLOY™ (zolbetuximab) Approved in Japan for Treatment of Gastric Cancer · Persbericht

22 maart 2024 · Astellas Receives Positive CHMP Opinion for XTANDI™ in Additional Recurrent Early Prostate Cancer Treatment Setting · Persbericht

11 maart 2024 · FDA Grants Orphan Drug and Pediatric Exclusivities for CRESEMBA® (isavuconazonium sulfate) for Invasive Aspergillosis and Invasive Mucormycosis in Children · Persbericht

4 maart 2024 · Astellas Initiates Phase 3 Clinical Studies of Fezolinetant for VMS Associated with Menopause in Japan · Persbericht

16 februari 2024 · PADCEV™ (enfortumab vedotin (genetical recombination)) with KEYTRUDA® (pembrolizumab (genetical recombination)) Granted Priority Review by Japan's Ministry of Health, Labour and Welfare for First-Line Treatment of Advanced Bladder Cancer · Persbericht

16 februari 2024 · Astellas and Kelonia Therapeutics Enter into Research and License Agreement to Develop Novel Immuno-Oncology Therapeutics · Persbericht

7 februari 2024 · Astellas Makes Announcement about Management Structure · Persbericht

1 februari 2024 · Astellas to Air New VEOZAH® (fezolinetant) TV Spot During the Super Bowl · Persbericht

31 januari 2024 · Astellas Submits Supplemental New Drug Application in Japan for PADCEV™ (enfortumab vedotin (genetical recombination)) with KEYTRUDA® (pembrolizumab (genetical recombination)) for First-Line Treatment of Advanced Bladder Cancer · Persbericht

31 januari 2024 · Astellas Announces Strategic Collaboration with Mass General Brigham · Persbericht

26 januari 2024 · European Medicines Agency Validates Type II Variation Application for PADCEV™ (enfortumab vedotin) with KEYTRUDA®(pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer · Persbericht

9 januari 2024 · Astellas Provides Update on Zolbetuximab Biologics License Application in U.S. · Persbericht

28 december 2023 · Elpiscience and Astellas Enter into Research Collaboration and License Agreement for Novel Bispecific Macrophage Engager · Persbericht

22 december 2023 · Astellas Completes Acquisition of Propella Therapeutics · Persbericht

Mijn selecties